Beverly S. Mitchell, MD, is the Deputy Director of the Stanford Comprehensive Cancer Center, and is the George E. Becker Professor of Medicine at Stanford University. Before joining the Stanford faculty, Dr. Mitchell lead the Molecular Therapeutics Program at UNC Chapel Hill's Lineberger Comprehensive Cancer Center, where she also served as Associate Director for Translational Research and Chief of the Division of Hematology/Oncology.

Dr. Mitchell received a bachelors degree in biochemistry from Smith College in Massachusetts and received her MD from Harvard Medical School. She completed her medical training as Chief Resident at the University of Washington. After completing a research fellowship at the Metabolic Laboratory at the University of Zurich in Switzerland she was awarded a Hematology Fellowship at the University of Michigan. Dr. Mitchell was a faculty member in the Departments of Medicine and Pharmacology at the University of Michigan for 16 years before moving to UNC.

Bev Mitchell has authored over 120 peer-reviewed articles. She served as President of the American Society of Hematology (ASH) and is Chair of the Medical and Scientific Affairs Committee and Vice Chair for Medical and Scientific Affairs of the Leukemia and Lymphoma Society of America.

Dr. Mitchell's research relates to the development of new therapies for hematologic malignancies. She has a long-standing interest in IMPDH as a therapeutic target and has published extensively on the regulation of this enzyme and the potential role of inhibitors in the treatment of leukemia in preclinical and clinical investigations.

• Ji Y, Gu J, Makhov AM, Griffith JD, Mitchell BS "Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic acid by GTP." J Biol Chem 2005; More
• Hunsucker SA, Mitchell BS, Spychala J "The 5'-nucleotidases as regulators of nucleotide and drug metabolism." Pharmacol Ther 2005; 107: 1: 1-30 More
• Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, Lager JJ, Stephens C, Levin J, Krenitsky T, Elion G, Mitchell BS "Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies." J Clin Oncol 2005; 23: 15: 3396-403 More
• Gu JJ, Santiago L, Mitchell BS "Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl." Blood 2005; 105: 8: 3270-7 More
• Spychala J, Lazarowski E, Ostapkowicz A, Ayscue LH, Jin A, Mitchell BS "Role of estrogen receptor in the regulation of ecto-5'-nucleotidase and adenosine in breast cancer." Clin Cancer Res 2004; 10: 2: 708-17 More